Modulation of Endoplasmic Reticulum Stress in Experimental Anti-Cancer Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136407 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Natalia Ivanovna Agalakova. Beteiligte Einrichtung: Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 44 Thorez Avenue, Saint-Petersburg 194223, Russia. Hauptthemen laut MEDLINE: Endoplasmic Reticulum Stress, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 245 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: free disccount, Federal Agency of Scientific Organizations of Russia.
Abstract (Originalsprache)
The growth of tumor cells is accompanied by an increased rate of endoplasmic reticulum stress (ERS), the accumulation of misfolded proteins, and the activation of a network of adaptive signaling pathways known as the unfolded protein response (UPR). Although the UPR is an adaptive reaction aiming to restore ER proteostasis, prolonged and severe ERS leads to cell death. Taking into account that the components of the ERS/UPR machinery in cancers of different types can be overexpressed or downregulated, both the induction of excessive ERS and suppression of UPR have been proposed as therapeutic strategies to sensitize cells to conventional chemotherapy. This narrative review presents a several examples of using natural and synthetic compounds that can either induce persistent ERS by selectively blocking ER Ca2+ pumps (SERCA) to disrupt ER Ca2+ homeostasis, or altering the activity of UPR chaperones and sensors (GRP78, PERK, IRE1α, and ATF6) to impair protein degradation signaling. The molecular alterations induced by miscellaneous inhibitors of ERS/UPR effectors are described as well. These agents showed promising therapeutic effects as a part of combination therapy in preclinical experimental settings; however, the number of clinical trials is still limited, while their results are inconsistent. Multiple side effects, high toxicity to normal cells, or poor bioavailability also hampers their clinical application. Since the pharmacological modulation of ERS/UPR is a valuable approach to sensitize cancer cells to standard chemotherapy, the search for more selective agents with better stability and low toxicity, as well as the development of more efficient delivery systems that can increase their therapeutic specificity, are highly required goals for future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 44 Thorez Avenue, Saint-Petersburg 194223, Russia.
ORCID-Profile: Natalia Ivanovna Agalakova
Förderung
- free disccount
- Federal Agency of Scientific Organizations of Russia
Zitieren
APA
Agalakova, N. I. (2025). Modulation of Endoplasmic Reticulum Stress in Experimental Anti-Cancer Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136407
Vancouver
Agalakova NI. Modulation of Endoplasmic Reticulum Stress in Experimental Anti-Cancer Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136407
BibTeX
@article{Agalakova2025,
author = {Agalakova, Natalia Ivanovna},
title = {Modulation of Endoplasmic Reticulum Stress in Experimental Anti-Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136407}
}
EUVIMED